Customer concentration
A small number of customers account for most product revenue and receivables.
- Scope
- Four customers over 90% of gross product revenue
- Materiality
- high
Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. is a U.S.-based commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases. Its business combines marketed prescription products, specialty-pharmacy distribution, and a proprietary formulation platform used to develop injectable medicines.
9,0 %
0,2 %
+43,7 %
2.19
1.57
| % | |
|---|---|
| Commercial endocrine therapies | 45% Approved products for endocrine disorders and related rare diseases. |
| Glucagon rescue products | 35% Gvoke products used to treat severe hypoglycemia. |
| Rare neuromuscular therapy | 15% Keveyis for Primary Periodic Paralysis. |
| Pipeline and technology partnerships | 5% XP-8121 development and formulation collaborations using XeriSol/XeriJect. |
Xeris sells primarily to pharmaceutical wholesalers and specialty pharmacies, which then distribute products to...
- Pharmaceutical wholesalersprimary
Buy finished Recorlev, Gvoke, and Keveyis for broad downstream distribution.
- Specialty pharmaciesprimary
Dispense the company’s products to patients and manage specialty access workflows.
- Patients with rare endocrine disordersprimary
Use Recorlev for Cushing’s syndrome and related hypercortisolemia treatment.
- Patients at risk of severe hypoglycemiaprimary
Use Gvoke rescue products for emergency glucagon administration.
- Patients with Primary Periodic Paralysissecondary
Use Keveyis to treat PPP and related variants.
- Pharmaceutical collaboration partnersemerging
Engage Xeris for formulation development using XeriSol and XeriJect.
Xeris generates revenue primarily in the United States and markets its approved products there...
- •Commercial sales are concentrated in the United States
- •Recorlev, Gvoke, and Keveyis are sold in the U.S.
- •API and drug product supply rely on third-party manufacturers
- •Key supply chain locations include Switzerland, Taiwan, California, Florida, Illinois
- •Cross-border sourcing increases supply continuity and quality-control exposure
Xeris’ strategy is to expand the commercial reach of Recorlev, Gvoke, and Keveyis while advancing XP-8121 through...
01
Expand commercial productsshort-term
The company’s current revenue base depends on Recorlev, Gvoke, and Keveyis.
02
Advance XP-8121medium-term
A late-stage levothyroxine product could broaden the endocrine franchise.
03
Monetize formulation technologymedium-term
Partnerships can create non-product revenue and validate XeriSol/XeriJect.
04
Preserve outsourced operating modellong-term
Third-party manufacturing and distribution keep capital intensity lower.
Xeris depends on a small number of customers, third-party manufacturers, and a limited set of commercial products, so...
Single-source and third-party supply dependence
Key APIs and drug products are sourced from external manufacturers.
- Scope
- Regis, Lonza, Bachem, Pyramid, SHL, Taro
- Materiality
- high
Regulatory and clinical development risk
XP-8121 and other pipeline efforts require FDA review and successful trials.
- Scope
- Phase 3 planning and approval pathway
- Materiality
- high
Reimbursement and pricing pressure
Net revenue depends on rebates, chargebacks, discounts, and payer access.
- Scope
- Specialty pharmacy and wholesaler channel
- Materiality
- high
Financing risk
The company may need additional capital to fund commercialization and R&D.
- Scope
- Public or private debt/equity financing
- Materiality
- high
Intellectual property risk
Value depends on protecting proprietary formulation science and product rights.
- Scope
- XeriSol, XeriJect, XP-8121
- Materiality
- medium
Gross-to-net revenue reserves
Can materially change net sales versus gross shipments
Revenue recognition timing
Quarterly revenue can shift with channel inventory and ordering patterns
Inventory and purchase commitments
Can affect cost of goods sold and reserve estimates
Collaboration/royalty revenue
Adds variability outside core product sales
: 29.4.2026